# US 8,658,177 B2 · Promiscuous HER-2/Neu CD4 T cell epitopes

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,658,177 B2
- Document ID: US8658177B2
- Status: Granted
- Kind: B2
- Application number: 13/587,619
- Filed: 2012-08-16
- Published: 2012-12-06
- Granted: 2014-02-25
- Earliest claimed: 2006-08-11
- Assignees: Dendreon Corporation
- Applicants: Jami B. Wollan; Lori A. Jones
- Inventors: Jami B. Wollan; Lori A. Jones
- Web page: https://patentgrep.com/patent/US8658177B2

## CPC

- C07K 14/71: for growth factors; for growth regulators
- A61P 35/00: Antineoplastic agents
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/04: Immunostimulants
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention relates to the discovery of novel T cell epitopes of the human HER-2/Neu protein that is promiscuous for at least 25 different HLA-DR alleles. The invention also relates to compositions that contain one of the novel epitopes or a fusion peptide of such a epitope and a heterologous polypeptide. Further disclosed herein is the use of the epitopes or their fusion peptides, and compositions containing the epitopes or their fusion peptides.

## Claims

### Claim 1

A method for inducing in a patient a T cell immune response specific to a HER-2/Neu protein, the method comprising the step of administering an effective amount of a composition comprising a peptide consisting of the amino acid sequence of SEQ ID NO: 2, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 31 to the patient.

### Claim 2 (depends on 1)

The method of claim 1, wherein the composition comprises a fusion protein comprising the peptide and a heterologous polypeptide.

### Claim 3 (depends on 2)

The method of claim 2, wherein the peptide is fused to the heterologous polypeptide via a peptide bond.

### Claim 4

The method of claim, wherein the heterologous polypeptide is a granulocyte-macrophage colony-stimulating factor (GM-CSF).

### Claim 5 (depends on 2)

The method of claim 2, wherein the peptide has the amino acid sequence of SEQ ID NO:2.

### Claim 6 (depends on 1)

The method of claim 1, wherein the composition comprises a physiologically acceptable excipient.

### Claim 7 (depends on 1)

The method of claim 1, wherein the peptide is selected from the group consisting of: SEQ ID NOs: 20, 21, 22, or 23.

### Claim 8 (depends on 1)

The method of claim 1, wherein the peptide is selected from the group consisting of: SEQ ID NOs: 24, 25, or 26.

### Claim 9 (depends on 1)

The method of claim 1, wherein the peptide is selected from the group consisting of: SEQ ID NOs: 27, 28, 29, or 31.

### Claim 10 (depends on 1)

The method of claim 1, wherein the peptide has the amino acid sequence of SEQ ID NO:2.